Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.

Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K.

JAMA Oncol. 2019 Aug 15:e191870. doi: 10.1001/jamaoncol.2019.1870. [Epub ahead of print]

PMID:
31415071
2.

Trends in Medical Aid in Dying in Oregon and Washington.

Al Rabadi L, LeBlanc M, Bucy T, Ellis LM, Hershman DL, Meyskens FL Jr, Taylor L, Blanke CD.

JAMA Netw Open. 2019 Aug 2;2(8):e198648. doi: 10.1001/jamanetworkopen.2019.8648.

3.

Comment on "A Roadmap for Aspiring Surgeon-Scientists in Today's Healthcare Environment".

Vega EA, Ellis LM.

Ann Surg. 2019 Apr 23. doi: 10.1097/SLA.0000000000003334. [Epub ahead of print] No abstract available.

PMID:
31021829
4.

Scientific Integrity and Data Accuracy.

Disis MLN, Ellis LM.

JAMA Oncol. 2019 May 1;5(5):745. doi: 10.1001/jamaoncol.2019.0656. No abstract available.

PMID:
30920610
5.

Inhibition of PGE2/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress.

Huang H, Aladelokun O, Ideta T, Giardina C, Ellis LM, Rosenberg DW.

Sci Rep. 2019 Mar 20;9(1):4954. doi: 10.1038/s41598-019-40848-4.

6.

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.

Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E.

Ann Oncol. 2018 Oct 1;29(10):2061-2067. doi: 10.1093/annonc/mdy337.

PMID:
30412224
7.

Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology.

Parseghian CM, Tam AL, Yao J, Ensor J Jr, Ellis LM, Raghav K, Overman MJ.

JAMA Oncol. 2019 Mar 1;5(3):402-405. doi: 10.1001/jamaoncol.2018.4640.

PMID:
30383128
8.

Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion.

Wang R, Bhattacharya R, Ye X, Fan F, Boulbes DR, Ellis LM.

Mol Cancer Res. 2019 Jan;17(1):20-29. doi: 10.1158/1541-7786.MCR-18-0341. Epub 2018 Aug 21.

PMID:
30131447
9.

Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials.

Overman MJ, Ellis LM, Joffe S.

JAMA Oncol. 2018 Aug 1;4(8):1041-1042. doi: 10.1001/jamaoncol.2018.1002. No abstract available.

PMID:
29799989
10.

A Survey on Data Reproducibility and the Effect of Publication Process on the Ethical Reporting of Laboratory Research.

Boulbes DR, Costello T, Baggerly K, Fan F, Wang R, Bhattacharya R, Ye X, Ellis LM.

Clin Cancer Res. 2018 Jul 15;24(14):3447-3455. doi: 10.1158/1078-0432.CCR-18-0227. Epub 2018 Apr 11.

11.

Macrophage conditioned medium promotes colorectal cancer stem cell phenotype via the hedgehog signaling pathway.

Fan F, Wang R, Boulbes DR, Zhang H, Watowich SS, Xia L, Ye X, Bhattacharya R, Ellis LM.

PLoS One. 2018 Jan 2;13(1):e0190070. doi: 10.1371/journal.pone.0190070. eCollection 2018.

12.

It Is Time to Re-Evaluate the Peer Review Process for Preclinical Research.

Bhattacharya R, Ellis LM.

Bioessays. 2018 Jan;40(1). doi: 10.1002/bies.201700185. Epub 2017 Dec 11.

13.

Underreporting of Research Biopsies from Clinical Trials in Oncology.

Parseghian CM, Raghav K, Wolff RA, Ensor J Jr, Yao J, Ellis LM, Tam AL, Overman MJ.

Clin Cancer Res. 2017 Nov 1;23(21):6450-6457. doi: 10.1158/1078-0432.CCR-17-1449. Epub 2017 Jul 28.

14.

Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion.

Bhattacharya R, Fan F, Wang R, Ye X, Xia L, Boulbes D, Ellis LM.

Br J Cancer. 2017 Sep 5;117(6):848-855. doi: 10.1038/bjc.2017.238. Epub 2017 Jul 25.

15.

Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors.

Ye X, Wang R, Bhattacharya R, Boulbes DR, Fan F, Xia L, Adoni H, Ajami NJ, Wong MC, Smith DP, Petrosino JF, Venable S, Qiao W, Baladandayuthapani V, Maru D, Ellis LM.

Cancer Prev Res (Phila). 2017 Jul;10(7):398-409. doi: 10.1158/1940-6207.CAPR-16-0178. Epub 2017 May 8.

16.

Endothelial cells activate the cancer stem cell-associated NANOGP8 pathway in colorectal cancer cells in a paracrine fashion.

Wang R, Bhattacharya R, Ye X, Fan F, Boulbes DR, Xia L, Ellis LM.

Mol Oncol. 2017 Aug;11(8):1023-1034. doi: 10.1002/1878-0261.12071. Epub 2017 Jun 6.

17.

Preclinical data: Three-point plan for reproducibility.

Balas EA, Ellis LM.

Nature. 2017 Mar 1;543(7643):40. doi: 10.1038/543040d. No abstract available.

PMID:
28252077
18.

Words matter: Restoring respect and dignity when referring to individuals with cancer.

Ellis LM, Blanke CD, Kohn EC.

Cancer. 2017 Jul 1;123(13):2390-2391. doi: 10.1002/cncr.30625. Epub 2017 Feb 9. No abstract available.

19.

Reply to "Improving Microbiology Research: the Problems Are Less Statistical and More Biological".

Casadevall A, Ellis LM, Davies EW, McFall-Ngai M, Fang FC.

MBio. 2016 Oct 18;7(5). pii: e01680-16. doi: 10.1128/mBio.01680-16. No abstract available.

20.

A Framework for Improving the Quality of Research in the Biological Sciences.

Casadevall A, Ellis LM, Davies EW, McFall-Ngai M, Fang FC.

MBio. 2016 Aug 30;7(4). pii: e01256-16. doi: 10.1128/mBio.01256-16.

21.

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.

Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S.

Oncotarget. 2016 Aug 23;7(34):54627-54631. doi: 10.18632/oncotarget.10559.

22.

Therapy: Colorectal cancer: how to teach an old drug new tricks.

Grothey A, Ellis LM.

Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):384-5. doi: 10.1038/nrgastro.2016.87. Epub 2016 May 25. No abstract available.

PMID:
27251212
23.

Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.

Bhattacharya R, Ye XC, Wang R, Ling X, McManus M, Fan F, Boulbes D, Ellis LM.

Cancer Res. 2016 May 15;76(10):3014-24. doi: 10.1158/0008-5472.CAN-15-1605. Epub 2016 Mar 17.

24.

Antiangiogenic therapy in oncology: current status and future directions.

Jayson GC, Kerbel R, Ellis LM, Harris AL.

Lancet. 2016 Jul 30;388(10043):518-29. doi: 10.1016/S0140-6736(15)01088-0. Epub 2016 Feb 5. Review.

PMID:
26853587
25.

A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling.

Wang R, Ye X, Bhattacharya R, Boulbes DR, Fan F, Xia L, Ellis LM.

Stem Cells Transl Med. 2016 Mar;5(3):331-8. doi: 10.5966/sctm.2015-0168. Epub 2016 Jan 7.

26.

From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.

Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ.

J Clin Oncol. 2015 Nov 1;33(31):3583-90. doi: 10.1200/JCO.2015.62.4148. Epub 2015 Aug 24. Review.

27.

CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.

Camp ER, Ellis LM.

Clin Cancer Res. 2015 Aug 15;21(16):3578-80. doi: 10.1158/1078-0432.CCR-14-2900.

28.

Losing "Losing the Battle With Cancer".

Ellis LM, Blanke CD, Roach N.

JAMA Oncol. 2015 Apr;1(1):13-4. doi: 10.1001/jamaoncol.2014.188. No abstract available.

PMID:
26182295
29.

The erosion of research integrity: the need for culture change.

Ellis LM.

Lancet Oncol. 2015 Jul;16(7):752-4. doi: 10.1016/S1470-2045(15)00085-6. Review. No abstract available.

PMID:
26149871
30.

VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells.

Ye X, Fan F, Bhattacharya R, Bellister S, Boulbes DR, Wang R, Xia L, Ivan C, Zheng X, Calin GA, Wang J, Lu X, Ellis LM.

Mol Cancer Res. 2015 Sep;13(9):1274-82. doi: 10.1158/1541-7786.MCR-15-0061. Epub 2015 Jun 3.

31.

TP53 loss creates therapeutic vulnerability in colorectal cancer.

Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X.

Nature. 2015 Apr 30;520(7549):697-701. doi: 10.1038/nature14418. Epub 2015 Apr 22.

32.

The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells.

Fan F, Bellister S, Lu J, Ye X, Boulbes DR, Tozzi F, Sceusi E, Kopetz S, Tian F, Xia L, Zhou Y, Bhattacharya R, Ellis LM.

Br J Cancer. 2015 Feb 3;112(3):539-46. doi: 10.1038/bjc.2014.620. Epub 2014 Dec 23.

33.

Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.

Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S.

Clin Cancer Res. 2015 Feb 15;21(4):899-906. doi: 10.1158/1078-0432.CCR-14-0894. Epub 2014 Dec 16.

34.

Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR.

Nat Rev Clin Oncol. 2015 Apr;12(4):197-212. doi: 10.1038/nrclinonc.2014.202. Epub 2014 Nov 25. Review.

PMID:
25421275
35.

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.

Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS.

Clin Cancer Res. 2014 Dec 1;20(23):5956-63. doi: 10.1158/1078-0432.CCR-14-1582. Epub 2014 Oct 14.

36.

Therapeutic silencing of KRAS using systemically delivered siRNAs.

Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK.

Mol Cancer Ther. 2014 Dec;13(12):2876-85. doi: 10.1158/1535-7163.MCT-14-0074. Epub 2014 Oct 3.

37.

Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ.

Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521. Review.

38.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE.

J Clin Oncol. 2014 Apr 20;32(12):1277-80. doi: 10.1200/JCO.2013.53.8009. Epub 2014 Mar 17. No abstract available.

PMID:
24638016
39.

Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.

Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan F, Ellis LM, Formstecher P, Van Seuningen I, Gespach C, Polakowska R, Huet G.

Clin Cancer Res. 2014 Feb 15;20(4):837-46. doi: 10.1158/1078-0432.CCR-13-1854. Epub 2013 Dec 9.

40.

Analysis of LGR4 receptor distribution in human and mouse tissues.

Yi J, Xiong W, Gong X, Bellister S, Ellis LM, Liu Q.

PLoS One. 2013 Oct 21;8(10):e78144. doi: 10.1371/journal.pone.0078144. eCollection 2013.

41.

miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.

Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L, Calin GA, Ellis LM, Lu X.

Mol Oncol. 2014 Feb;8(1):83-92. doi: 10.1016/j.molonc.2013.09.004. Epub 2013 Oct 8.

42.

Generation of monoclonal antibody MS17-57 targeting secreted alkaline phosphatase ectopically expressed on the surface of gastrointestinal cancer cells.

Li M, Gao J, Feng R, Wang Y, Chen X, Sun J, Zhang D, Zhu Z, Ellis LM, Lu M, Lee JE, Feng Z, Liu B.

PLoS One. 2013 Oct 15;8(10):e77398. doi: 10.1371/journal.pone.0077398. eCollection 2013.

43.

ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.

Zhou Y, Bollu LR, Tozzi F, Ye X, Bhattacharya R, Gao G, Dupre E, Xia L, Lu J, Fan F, Bellister S, Ellis LM, Weihua Z.

Mol Cancer Ther. 2013 Dec;12(12):2782-91. doi: 10.1158/1535-7163.MCT-13-0098. Epub 2013 Oct 16.

44.

An audience with : Lee M. Ellis. Interviewd by Man Tsuey Tse.

Ellis LM.

Nat Rev Drug Discov. 2013 Aug;12(8):572-3. doi: 10.1038/nrd4085. Epub 2013 Jul 19. No abstract available.

PMID:
23868111
45.

DNA-damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway.

Wan G, Zhang X, Langley RR, Liu Y, Hu X, Han C, Peng G, Ellis LM, Jones SN, Lu X.

Cell Rep. 2013 Jun 27;3(6):2100-12. doi: 10.1016/j.celrep.2013.05.038. Epub 2013 Jun 20.

46.

A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic.

Mobley A, Linder SK, Braeuer R, Ellis LM, Zwelling L.

PLoS One. 2013 May 15;8(5):e63221. doi: 10.1371/journal.pone.0063221. Print 2013.

47.

Predictive biomarkers for bevacizumab: are we there yet?

Maru D, Venook AP, Ellis LM.

Clin Cancer Res. 2013 Jun 1;19(11):2824-7. doi: 10.1158/1078-0432.CCR-12-3409. Epub 2013 Apr 2.

48.

Negotiating identity development among undocumented immigrant college students: a grounded theory study.

Ellis LM, Chen EC.

J Couns Psychol. 2013 Apr;60(2):251-64. doi: 10.1037/a0031350. Epub 2013 Feb 18.

PMID:
23421773
49.

Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1.

Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I, Maru DM, Hawke DH, Rak J, Mani SA, Zweidler-McKay P, Ellis LM.

Cancer Cell. 2013 Feb 11;23(2):171-85. doi: 10.1016/j.ccr.2012.12.021. Epub 2013 Jan 31.

50.

Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.

Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, Ellis LM.

Cancer Med. 2012 Aug;1(1):5-16. doi: 10.1002/cam4.4. Epub 2012 Jun 8.

Supplemental Content

Loading ...
Support Center